|
|
Post by winner on Jan 18, 2022 8:03:01 GMT -5
Thanks for the post hellodolly. Made my day.
|
|
|
|
Post by mango on Jan 18, 2022 8:05:06 GMT -5
What a monumental time to be a MannKind Shareholder!
🥭 Tyvaso DPI approval NEXT MONTH
🥭 UT royalties begin THIS YEAR
|
|
|
|
Post by winner on Jan 18, 2022 8:09:10 GMT -5
Sorry. Credit should go to brianrocco. Well done Brian. I am enjoying my morning coffee and repeatedly reading the press release.
|
|
|
|
Post by peppy on Jan 18, 2022 8:10:35 GMT -5
Class 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. Nice work brianrocco , thank you for posting. In my world, this explains Fridays MNKD price pop, and UTHR is on the verge of a new all time high. Price is moving, The dates are set? |
|
|
|
Post by Clement on Jan 18, 2022 8:36:35 GMT -5
Class 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. Please provide a link. |
|
|
|
Post by sportsrancho on Jan 18, 2022 8:43:58 GMT -5
|
|
|
|
Post by dg1111 on Jan 18, 2022 8:44:16 GMT -5
Class 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. Please provide a link. |
|
|
|
Post by rayskum on Jan 18, 2022 8:45:17 GMT -5
|
|
|
|
Post by peppy on Jan 18, 2022 8:49:25 GMT -5
Class 1 Response!! Hot off the press: On October 18, 2021, United Therapeutics Corporation (the Company) issued a press release disclosing that it had received a Complete Response from the U.S. Food and Drug Administration (the FDA) concerning the Company’s new drug application (NDA) for Tyvaso DPI™. On December 27, 2021, the Company disclosed that it had resubmitted the NDA to the FDA. Today, the Company discloses that the FDA has acknowledged acceptance of the NDA for review as a class 1 response with a user fee goal date in February 2022. Please provide a link. Looked, I could not find a link. MNKD price just traded $4.00 premarket. UTHR trading up. According to Yahoo. 215.83 +1.87 (+0.87%) Pre-Market: 08:14AM EST The market is in a mood. Did you see interest rates pop Friday? MNKD financing is locked in for a while.  |
|
|
|
Post by cretin11 on Jan 18, 2022 10:22:38 GMT -5
I'll go with Martine's optimism and $100M bet on this one versus the shorts thinking there's a real possibility this is going to be delayed. Let's see what the price action says in response to this announcement. Today should be a good day. Agree, the shorts have the wrong end of that bet, I’m betting with Martine. |
|
|
|
Post by uvula on Jan 18, 2022 10:34:53 GMT -5
What a monumental time to be a MannKind Shareholder! 🥭 Tyvaso DPI approval NEXT MONTH 🥭 UT royalties begin THIS YEAR Good news today but we've been here before. I'm cautiously optimistic but not assuming anything. |
|
